Engels

Researchers are evaluating the efficacy and safety of the drug Ranquilon compared to Afobazole in adults with anxiety disorders caused by neurasthenia and adjustment disorders. This Phase IV, open-label, randomized, multicenter study aims to compare these treatments in patients aged 18 to 70 years who have specific anxiety levels and meet defined diagnostic criteria. Participants will receive either Ranquilon tablets at a dose of 6 mg per day or Afobazole tablets at 30 mg per day for 28 days. The study includes assessments at baseline and on Day 29, with safety and tolerability monitored through various clinical tests and vital signs up to Day 43. The trial evaluates anxiety reduction and other related symptoms using scales like the Hamilton Anxiety Rating Scale and Clinical Global Impression. During the study, participants will undergo multiple evaluations including blood tests, urinalysis, and assessments of anxiety, fatigue, depression, and suicidal thoughts. Researchers will track adverse events and treatment adherence, with the primary outcome measured by the proportion of patients achieving a significant reduction in anxiety by Day 29. The study concludes with safety follow-up to Day 43, ensuring comprehensive monitoring of participants throughout the trial.

Researchers are evaluating the drug 4-MUST to understand its effectiveness, safety, and tolerability in treating patients with chronic cholecystitis and biliary dyskinesia. This study compares different doses of 4-MUST with a placebo to see how well the drug reduces upper abdominal pain and gastrointestinal symptoms. The trial is a phase 2, prospective, randomized, double-blind, placebo-controlled study designed to provide detailed insight into the drugs impact on these digestive conditions. Participants will be randomly assigned to one of four groups. One group receives 1 tablet of 4-MUST 128 mg plus 2 placebo tablets three times daily, another receives 2 tablets of 4-MUST 256 mg plus 1 placebo tablet three times daily, a third group takes 3 tablets of 4-MUST 384 mg three times daily, and the last group receives 3 placebo tablets three times daily. The treatment lasts for 29 days, with doses given three times a day, followed by assessment and monitoring. During the study, participants will undergo regular evaluations including pain measurement using a Visual Analog Scale VAS, gastrointestinal symptom rating via questionnaires, and quality of life assessments with the SF-36 questionnaire. Safety will be monitored through adverse event tracking, physical examinations, vital signs, laboratory tests, and electrocardiograms at multiple time points throughout the 29-day period and up to day 36. These thorough assessments aim to capture the drugs effects and tolerability over the course of treatment.

Researchers are studying the quality of primary health care for patients with arterial hypertension, a common condition that significantly impacts population health and mortality. This observational study uses data from a cardiovascular disease registry to analyze how well medical care aligns with current clinical recommendations. The research aims to identify trends and improve treatment approaches for patients with hypertension, including secondary forms. The study collects medical data through a computerized arterial hypertension registry with remote access, allowing online entry of patient information from outpatient records. Doctors received training to reduce data entry errors, and a user guide was provided. Patients aged 18 and older with diagnosed hypertension have their anonymized examination and treatment data added to the registry after giving informed consent. Participants involvement includes the collection of medical data from their outpatient records, which is transmitted securely and anonymously. Researchers will monitor outcomes such as the number of patients achieving blood pressure control below 14090 mm Hg and track histories of related conditions like myocardial infarction, chronic kidney disease, heart failure, and atrial fibrillation. The study also observes the use of antihypertensive medications over the period from 2018 to 2021, with ongoing data collection and analysis.

This research aims to evaluate the effectiveness and safety of different doses of the drug Grammidin with anesthetic, delivered as a metered dose topical spray, for treating acute infectious and inflammatory diseases of the pharynx. These conditions include acute pharyngitis, nasopharyngitis, and exacerbation of chronic pharyngitis. The study compares Grammidin spray with Septolete Total lozenges as an active comparator in a Phase 2 randomized trial. Participants are assigned to one of three groups one group receives Grammidin spray with 2 sprays every 6 hours three times daily for 7 days, another group receives Grammidin spray with 4 sprays on the same schedule, and the third group takes Septolete Total lozenges 1 lozenge every 6 hours, up to 3 lozenges daily for 7 days. Treatments are taken under fed conditions. The study is open-label, multicenter, and parallel-group. During the 8-day study period, participants attend visits on Day 1, Day 5, and Day 8 for assessments including sore throat severity measured by Visual Analog Scale VAS and the Clinical Symptom Severity Scale. Researchers monitor clinical symptoms, inflammation signs, and intoxication syndrome. Safety is evaluated through recording adverse events, vital signs, physical examinations, and multiple laboratory tests such as blood counts, blood chemistry, and urinalysis. The study tracks treatment adherence and overall patient outcomes over the three visits.